BridgeMD
New treatment option for Takayasu Arteritis
Official title A Pilot Study in Severe Patients With Takayasu Arteritis.
ClinicalTrials.gov ID: NCT04300686
What this study is testing
What is Tocilizumab?
Tocilizumab is an investigational medicine, given as an once-daily, being studied as a potential treatment for takayasu arteritis.
Also referred to as IL-6R alpha antibody.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Takayasu arteritis (TAK) is a rare chronic inflammatory arteritis, which lacks an effective well-accepted intervention strategy. We classify TAK patients into 3 levels, including mild, moderate, and severe.
- Phase 4: studies an already-approved treatment
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 14 to 100
You may be able to join if
- age≥14 years old;
- active: Kerr score≥ 2;
- severe:
- Blood pressure \> 180/110mmHg;
- ≥ 3 branches with the stenotic rate \> 70% involved;
You likely can't join if
- Severe organ insufficiency;
- Acute or chronic active infections including tuberculosis, hepatitis virus, etc.;
- Other autoimmune diseases including systemic lupus erythematosus, Behcet disease, IgG4 relative disease;
- malignant tumors;
- history of severe drug allergy;
- successive twice relapse occurs even after the intervention adjustment ( for the benefits of patients)
See the full eligibility criteria
- age≥14 years old;
- active: Kerr score≥ 2;
- severe:
- Blood pressure \> 180/110mmHg;
- ≥ 3 branches with the stenotic rate \> 70% involved;
- high degree of organ insufficiency: NYHF III\~IV; eGFR (MRDR) 15\~ 60ml/min;
- Severe organ insufficiency;
- Acute or chronic active infections including tuberculosis, hepatitis virus, etc.;
- Other autoimmune diseases including systemic lupus erythematosus, Behcet disease, IgG4 relative disease;
- malignant tumors;
- history of severe drug allergy;
- successive twice relapse occurs even after the intervention adjustment ( for the benefits of patients)
The study team makes the final eligibility decision.
Where it's taking place
- Shanghai, Shanghai Municipality, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 14 years to 100 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Shanghai, Shanghai Municipality, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.